Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ANLN siRNA
- Development stage
- Unknown
- Lead developer
- Alnylam Pharmaceuticals
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
ANLN siRNA (also known as siAnln) is a research-stage RNA interference (RNAi) therapeutic designed to silence the expression of the ANLN gene, which encodes the actin-binding scaffolding protein anillin. Developed in partnership with Alnylam Pharmaceuticals and researchers at the University of Texas Southwestern (UTSW) Medical Center, the therapeutic is formulated as a GalNAc (N-acetylgalactosamine)-conjugated siRNA to enable selective, receptor-mediated uptake by hepatocytes via the asialoglycoprotein receptor. Knockdown of ANLN in hepatocytes inhibits cytokinesis and promotes hepatocyte polyploidization, a natural physiological mechanism that protects the liver from malignant transformation. Preclinical studies in multiple autochthonous mouse models of hepatocellular carcinoma (HCC) and metabolic dysfunction-associated steatohepatitis (MASH) have demonstrated that ANLN siRNA is safe, prevents cancer development, and improves overall survival. It is being evaluated in an investigator-initiated Phase Ia dose-escalation adjuvant clinical trial to reduce the risk of de novo recurrence in patients with HCC undergoing locoregional therapy.
- Other names
- ANLN-siRNAGalNAc-siANLNanillin siRNAsiANLN
02
Targets
Cytoskeleton (Cytoskeletal regulators)
Beyond the preview
Go deeper on ANLN siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ANLN siRNA.